atropine sulfate drops
Selected indexed studies
- Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. (Ophthalmology, 2019) [PMID:30514630]
- Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. (JAMA Ophthalmol, 2023) [PMID:37440213]
- Advances in myopia control strategies for children. (Br J Ophthalmol, 2025) [PMID:38777389]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. (2023) pubmed
- Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. (2019) pubmed
- Advances in myopia control strategies for children. (2025) pubmed
- 0.01% Atropine Eye Drops in Children With Myopia and Intermittent Exotropia: The AMIXT Randomized Clinical Trial. (2024) pubmed
- Cost-Effectiveness Analysis of Myopia Progression Interventions in Children. (2023) pubmed
- Amblyopia: Detection and Treatment. (2019) pubmed
- Topical Atropine for Childhood Myopia Control: The Atropine Treatment Long-Term Assessment Study. (2024) pubmed
- Low-Concentration Atropine Eye Drops for Myopia Progression. (2023) pubmed
- Juvenile toxicity of atropine sulfate eye drops in young rats. (2025) pubmed
- Interventions to slow progression of myopia in children. (2020) pubmed